OBJECTIVE: To assess the contribution of a thermogenic effect to weight loss induced by eight weeks treatment with sibutramine (15mgad) vs placebo in obese subjects. DESIGN: Randomised, placebo controlled, double blind study. SUBJECTS: Thirty-two (7 male, 25 female) healthy obese body mass index (BMI) 33.9 AE 0.5 kgam 2 subjects completed the trial. MEASUREMENTS: Energy expenditure (EE) was measured by indirect calorimetry during a 32 h stay in a respiration chamber before and after 8 weeks treatment. Visual analogue scales were completed for assessment of appetite sensation. No dietary restriction was given. RESULTS: Sibutramine caused a signi®cant weight loss compared with placebo ( 7 2.4 kg vs 0.3 kg, P`0.001). Despite the larger weight loss after 8 weeks, 24-h EE did not decrease more in the sibutramine than in the placebo group ( 7 2.6% vs 7 2.5%, P ns). When the changes in 24-h EE were adjusted for changes in body weight, 24-h EE decreased signi®cantly less in the sibutramine group than in the placebo group (0.8% vs 3.8%, P`0.02). Sibutramine signi®cantly decreased both hunger and anticipated food consumption, and increased satiety scores. CONCLUSIONS: The weight reducing effect of sibutramine in humans is caused by a dual mechanism: reduction of energy intake by increasing satiety and decreasing hunger and prevention of the decline in EE that follows weight loss.
Introduction
The prevalence of obesity and its related co-morbidities is becoming an increasing global health problem. 1 Overweight develops from an imbalance between energy intake and energy expenditure, and current treatment regimes attempt to decrease energy intake by prescribing a low-fat, high-carbohydrate diet and to increase energy expenditure (EE) by encouraging increased physical activity. In many obese subjects this treatment is ineffective and does not produce a satisfactory long-term result. 2, 3 As a result adjuvant treatment regimes including pharmacological treatment are required.
Sibutramine is a novel antiobesity agent that acts as a serotonergic and noradrenergic reuptake inhibitor. 4 Several studies have shown that sibutramine, compared with placebo, produces clinically signi®cant weight losses in humans in a dose dependent manner, with the optimal dose being 10 ± 15 mgad. 5 ± 8 In rats, sibutramine causes weight loss through effects on both food intake and metabolic rate. 9 It increases satiety, thereby reducing energy intake, and stimulates thermogenesis to produce increases in EE of up to 30%. 9 In humans, as in rats, sibutramine decreases energy intake by increasing satiety and decreasing hunger. 10, 11 Moreover, we have recently shown that sibutramine 30 mg possesses thermogenic properties following acute administration in fasted and fed young, normal weight, males with the thermogenic effect being equivalent to 3 ± 5% of basal metabolic rate. 11 Whether the thermogenic properties of sibutramine, given in a daily recommended dose, contribute to its long-term weight reducing effect in obese subjects has not been elucidated. The aim of the present study was, therefore, to evaluate the acute and chronic effect before and after eight weeks treatment with sibutramine 15 mg daily on EE, body composition and appetite. The study was designed as a randomised, placebo controlled double blind trial.
Methods

Subjects
Thirty-eight obese, otherwise healthy, subjects, (eight males and thirty females) entered the study.
Six subjects did not complete the study, two due to adverse events (migraine and cold), two did not attend the second chamber stay because of personal problems, one had to leave the study prematurely for occupational reasons and the last subject did not complete the second 24 h measure of EE due to technical problems. The anthropometric data of the thirty-two subjects who completed the study are shown in Table 1 . None of the differences between the two treatment groups were signi®cant.
All subjects underwent a full medical history and physical examination, electrocardiogram, routine haematology, biochemistry and urine screening test, and all were found to be in good health except for obesity. They had all been weight stable ( AE 3 kg) for at least three months, according to their medical history. Informed consent was obtained according to the declaration of Helsinki II, and the study was approved by the Municipal Ethical Committee of Copenhagen and Frederiksberg.
Design
Body weight was measured on a decimal scale (Seca model 707, Copenhagen) and body composition was measured by DXA scan (DXA-scanning, Hologic, Inc, Waltham, MA, USA). Blood pressure and heart rates were measured automatically (UA ± 743, Tadeka, Japan). Sensations of satiety, hunger, fullness and anticipated food consumption were measured on 10 cm visual analogue scales (VAS) with words anchored at the end expressing the most positive or the most negative rating. 12 EE was measured by indirect calorimetry during a 32 h stay in a respiration chamber prior to and after eight weeks of oral treatment with sibutramine 15 mg or placebo. The ®rst dose of trial medication was given after an initial 24 h baseline measurement of EE. DXA-scanning was performed 3 ± 5 d prior to the ®rst chamber stay. The subjects continued taking the trial medication once daily and check-up visits were made every second week, when body weight, blood pressure, heart rate and any adverse events were recorded. At the end of the eight weeks of intervention another 32 h stay in the respiration chamber was carried out, followed 3 ± 5 d later by DXA-scanning. No dietary restrictions were required of the subjects during the eight weeks intervention, and they were instructed not to change their way of living with regards to food intake and physical activity.
EE and substrate oxidation rates were measured in two open-circuit respiratory chambers which have been described in detail previously. 13 The two respiratory chambers work independently, each having ā oor area of 6.5 m 2 and a volume of 14.7 m 3 equipped with facilities for a`pleasant' stay. The gas exchange of the subjects was calculated from measurements of oxygen and carbon dioxide concentrations (Hartman and Braun analysers, Frankfurt, Germany) at the outlet of the chamber and from measured air¯ow through the chambers. Protein oxidation was calculated from urinary nitrogen content in the 32 h collection. The room temperature was maintained constant at 24 C in the daytime and at 18 C in the night. EE and utilization rates of lipid and carbohydrate were calculated as described by Livesey and Elia. 14 Heart rate was continuously monitored by a telemetry system (Dialogue 2000; Danica Electronics, Denmark) and stored in a computer for subsequent analysis. Spontaneous physical activity (SPA) in the respiration chambers was assessed by two microwave radars (Zettler Ghz-Doppler Mime).
A standard protocol (Table 2 ) with ®xed sessions of physical activity, including three bouts of bicycling of 10 min each (75 W) was followed during the stay. Sleeping energy expenditure (SEE) was measured from 01.00 ± 06.00 h, basal metabolic rate (BMR) from 08.00 ± 09.00 h. VAS for hunger and satiety were completed hourly from 08.00 ± 23.00 h. The subjects were kept under 24 h surveillance by a laboratory technician in the daytime and by trained medical students at night.
The energy intake during the chamber stay was calculated to meet energy requirements determined according to the equation EE (kJa24 h) 123.0ÂFFM (kg) 31.0ÂFM (kg) 23.8ÂDE (duration of exercise in min) obtained by a multiple regression on data from previous studies. 15 The diet provided 45% energy from carbohydrate, 30% from fat and 15% from protein. The dietary energy content and composition were calculated using`DANKOST' dietary assessment software (National Food Agency, Sùborg, Denmark). Foods left were reweighed, and used in the calculation of actual energy and macronutrient intake.
Statistics
All results are presented as mean AE s.e.m. Group means were compared by Student's unpaired t-test. Changes in EE was tested by two-way ANOVA of repeated measurement with treatment and time as factors. Predictors of changes in 24-h EE were determined by forward stepwise regression analysis, and changes in 24-h EE were adjusted (EE adj for differences in both body weight as measured by weighing immediately before the chamber stays Anthropometric data for the two treatment groups, data are presented as mean AE sem. Body composition was measured by DXA-scanning. There were no signi®cant differences between the two groups.
Sibutramine and thermogenesis DL Hansen et al (DBW), as well as for differences in fat mass (DFM) and fat free mass (DFFM) as measured by DXAscanning using the equation described by Ravussin et al 16 
Results
Changes in body weight and composition
Sibutramine caused a signi®cant loss of body weight (P`0.001), due to loss of both fat (P`0.001) and fat free mass (P`0.001) during the eight weeks of treatment (Table 3) . Body weight as measured at the DXA-scanning was lower than that measured in connection with the chamber stays, and the discrepancy between the loss of body weight, and the loss of fatfree mass and fat mass as determined by DXA-scanning, was due to the fact that DXA-scannings were performed 3 ± 5 d before and after the chamber stay.
Energy expenditure (EE)
Achievement of energy balance is illustrated by results on 24-h EE and energy intake, which together with SPA and RQ non protein (RQ np ) are shown in (Table 4) . None of the differences in either energy balance, SPA or RQ np between the changes in the two treatment groups were statistically signi®cant. The changes in EE for the two treatment groups are shown in (Table 5 ). EE decreased in both treatment groups during the 8 weeks. A small decrease during sleep (SEE 1.00 ± 6.00 ) occurred in the sibutramine Data are presented as mean AE sem. Body weight was measured at the start of the two chamber stays, while body composition was estimated by DXA-scanning 3 ± 5 d before and after the chamber stays. group, while a small increase was observed in the placebo group. No drug effect was found when analysing the changes in EE between the two groups, except the changes in SEE, which disappeared when adjusting for changes in SPA during sleep. EE during daytime (09.00 ± 17.00) increased in both treatment groups from day 0 to day 1 (Table 5 ), due to a signi®cant increase in SPA in both treatment groups, no acute drug effect was found when comparing the increases in EE from day 0 (09.00 ± 17.00) to day 1 (09.00 ± 17.00) between the two groups. Forward stepwise analyses of regression showed that the change in 24-h EE could be explained by changes in body weight (P`0.02) and treatment (drug vs placebo) (P 0.05). Figure 1 shows the correlation between the changes in 24-h EE and changes in body weight (r 0.42, P`0.02). After adjustment for changes in body weight as measured by weighing just before the chamber stays, 24-h EE decreased by only 0.8% ( 7 0.06AE 0.07 kJamin) in the sibutramine group, compared with 3.8% ( 7 0.28AE 0.05 kJamin) in the placebo group (group difference: P`0.02, Table 6 ). No signi®cant difference in 24-h EE between the two groups was found when adjusting for changes in fat free mass as measured by DXA-scanning (Table 6 ). This is probably due to the fact that the DXA-scannings were performed 3 ± 5 d before or after the chamber stays, making the results from the scannings less representative of the actual changes in body composition occurring between the two measurements of 24-h EE.
Hunger, satiety, fullness and anticipated food consumption
The mean scores for anticipated food consumption, satiety, fullness and hunger are shown in Figure  2a Analysis of covariance with the fasting value as covariate showed no signi®cant difference in the AUC between the two groups on day 0, whereas sibutramine compared with placebo caused a signi®cant decrease in both hunger and anticipated food on day 1, day 56 and day 57 (Figure 2a,d) . Sibutramine also increased the AUC for satiety above placebo levels on both day 1 and 56 (P`0.05), whereas the difference on day 57 was not signi®cant (Figure 2b ). Sibutramine caused no signi®cant changes in the scores for fullness on any of the four days (Figure 2c ).
Heart rate and blood pressure
The mean diastolic blood pressure increased in the sibutramine group from 74.3 AE 3.1 mmHg at day 0 to 81.4AE 2.5 mmHg at day 56 (P`0.01), while it only increased from 72.2 AE 2.7 to 73.0 AE 2.2 in the placebo group (ns), the changes between the two treatment groups being signi®cant (P`0.05). No signi®cant changes were observed in systolic blood pressure in either group. Sibutramine caused a signi®cant increase in heart rate of 7.1 AE 2.1 vs 7 1.7 AE 1.2 beats per minute in the placebo group (P`0.001), and the changes in heart rate were correlated with the changes in 24-h EE (r 0.41, P`0.05, Figure 3 ).
Discussion
The major ®ndings of the present study were that, as noted by Weintraub et al, 9 sibutramine can cause loss of weight without the need to restrict energy intake, and that in spite of a larger weight loss in the sibutramine than in the placebo group, the reductions in 24-h EE were similar (sibutramine vs placebo: 7 2.6% vs 7 2.5%, P ns). As expected, the reductions in body weight were signi®cantly associated with reductions in 24-h EE, and the greater weight loss in the sibutramine group makes it dif®cult to compare the change sin 24-h EE. We therefore adjusted 24-h EE for changes in body weight, and found that the adjusted 24-h EE decreased signi®-cantly less in the sibutramine group compared with that of the placebo group. The present ®nding of a slight thermogenic effect during chronic treatment therefore validates and extends our previous ®nding of an acute thermogenic effect of sibutramine in normal weight, male subjects. 11 Whereas the acute thermogenic effect increases EE above baseline the lower chronic dose of sibutramine did not raise EE but did have a desired effect of disinhibiting the normal reduction in EE seen with decreasing energy intake and weight loss. The within subject coef®cient of variation for 24-h EE is fully comparable with that of other studies 13, 17, 20 and the effect found in the present study is very similar to the results reported by Astrup et al, who found that the decrease in 24-h EE was 3 ± 5% less after eight weeks of treatment with ephedrineacaffeine compared with placebo. 21 We observed that sleeping EE was slightly higher in the sibutramine group than the placebo group after 8 weeks. This could entirely be explained by sleeping SPA increased in the placebo group, which is in contrast to the normally observed decrease in sleeping EE brought about by adaptation from the ®rst to the second stay. It seems to be explained by a few subjects in the placebo group having a more restless sleep pattern during the second stay.
The only previous study addressing the thermogenic effect of sibutramine during chronic treatment failed to ®nd any effect on resting EE of neither 10 mgad nor 30 mga as compared to placebo during 8 weeks treatment. 22 This observation taken together with the present ®nding of a weak thermogenic effect of sibutramine emphasises that it may be dif®cult to detect the effect by short-term measurement of EE.
Sibutramine also had signi®cant effects on appetite scores recorded during the trial. Despite a low reproducibility of subjective appetite scores, 23 we found that sibutramine compared with placebo caused a signi®cant decrease in the meal-induced ratings of both hunger and anticipated food consumption, together with a signi®cant increase in satiety scores, whereas no effects were found on pre-meal scores. These ®ndings are in agreement with previous studies. For example, Rolls et al found that 2 weeks treatment with sibutramine (30 mgad) signi®cantly reduced premeal ratings of both hunger and anticipated food consumption compared with placebo in obese women, 10 and we found that acute administration of a single does of sibutramine (30 mg) signi®cantly increased satiety in normal weight, male subjects.
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In accordance with other studies, we found that sibutramine caused a signi®cant loss in both body weight, fat free mass and fat mass. 5 ± 8 The weight loss induced by sibutramine in the present study corresponds to a decrease in body weight of 0.325 kgaweek, which is comparable with weight losses obtained with other available pharmacological agents. 24 The discrepancy between the loss of fat free mass and fat mass and the loss in body weight as measured at the start of the chamber stays (Table 1) , might be explained by the fact that the DXA scans were performed 3 ± 5 d before the ®rst visit and 3 ± 5 d after the second chamber stay. This is also likely to be the main reason for our lack of correlation between change in 24-h EE and fat-free mass. Moreover, in several studies 24-h EE has been reported to be mainly determined by fat-free mass, 13, 16, 19, 25, 26 but other studies have demonstrated that total and 24-h EE are better correlated with body weight than with fat-free mass. 27 Further, Amatruda et al found that changes in total EE during weight loss were better correlated with changes in body weight than with fatfree mass. 28 In this study sibutramine induced a weight loss above that of placebo by 2.6 kg and assuming that 75% of the weight loss consisted of fat this represents an energy content of 76,000 kJ. The increase in adjusted 24-h EE induced by sibutramine above placebo was 0.22 kJamin, or 17,700 kJ if extrapolated to the 8 week period. This estimate suggests that the thermogenic effect of sibutramine could account for approximately 23% and decreased energy intake for 77% of the weight loss.
Like in several other studies we found that sibutramine compared with placebo caused a signi®cant increase in both heart rate and diastolic blood pressure. 5, 6 Obesity, on the other hand, is a major risk factor for the development of cardiovascular risk factors and atherosclerotic disorders such as coronary heart disease and stroke, diseases that are all aggravated by an increase in blood pressure and heart rate. 1, 29 Thus, the effects of sibutramine on both blood pressure and heart rate have to be taken into consideration when using sibutramine clinically. In our previous acute study of sibutramine we found a signi®cant correlation between increase in heart rate and thermogenic response in normal weight subjects 11 and suggested that the increase in heart rate was, in part, secondary to the increased heat production caused by sibutramine. The present observation of a signi®cant correlation between changes in 24-h EE and 24 h heart rate during 8 weeks of treatment of obese subjects (r 0.41) con®rms this ®nding. Part of the increased heart rate induced by sibutramine during acute and chronic treatment may therefore have a clear physiological basis and be less of a safety concern.
In human subjects, resting metabolic rate decreases during weight reduction, which is probably due to loss of fat-free mass, fat mass and lower sympathetic nervous system activity. 30 Moreover, several studies have found that the relative reduction in BMR is larger than the relative reduction in body weight. 31, 32 Other studies have indicated that a low BMR for a given body size and composition may be involved in some cases of obesity. Ravussin et al reported in a prospective study that subjects with a low adjusted BMR were at higher risk for subsequent weight gain than individuals with a high adjusted BMR. 33 Moreover, a meta-analysis of BMR on formerly obese subjects and matched controls found that the formerly obese had a highly signi®cant 3 ± 5 % lower BMR and a ®ve-fold higher risk of having a very low BMR than the never-obese. 26 Thus, if sibutramine has suf®cient thermogenic activity to attenuate the decline in metabolic rate, this will help maximise the impact of its effect on food intake and energy balance, thereby producing a better weight loss than could be achieved by energy restriction alone. Moreover, the slight thermogenic activity would allow body weight to become stabilised at a slightly higher, and more acceptable level of energy intake, and this should aid compliance during long term weight maintenance.
Conclusion
The present study indicates that the weight reducing effect of sibutramine in humans, as in animal studies, is caused by a dual mechanism, mainly by reducing energy intake by increasing satiety and decreasing hunger and slightly increasing EE and preventing the decline in 24-h EE that follows weight loss.
